Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.75
CTIX's Cash to Debt is ranked lower than
67% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. CTIX: 2.75 )
Ranked among companies with meaningful Cash to Debt only.
CTIX' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 3.12 Max: No Debt
Current: 2.75
F-Score: 2
Z-Score: -1.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -364.49
CTIX's ROE (%) is ranked lower than
96% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. CTIX: -364.49 )
Ranked among companies with meaningful ROE (%) only.
CTIX' s ROE (%) Range Over the Past 10 Years
Min: -364.49  Med: -257.35 Max: -235
Current: -364.49
-364.49
-235
ROA (%) -112.65
CTIX's ROA (%) is ranked lower than
88% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. CTIX: -112.65 )
Ranked among companies with meaningful ROA (%) only.
CTIX' s ROA (%) Range Over the Past 10 Years
Min: -2870.38  Med: -215.36 Max: -99.77
Current: -112.65
-2870.38
-99.77
ROC (Joel Greenblatt) (%) -19381.66
CTIX's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. CTIX: -19381.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CTIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -41215.38  Med: -33618.18 Max: -19381.66
Current: -19381.66
-41215.38
-19381.66
EBITDA Growth (3Y)(%) 46.30
CTIX's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. CTIX: 46.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CTIX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.7  Med: 46.75 Max: 94.9
Current: 46.3
-5.7
94.9
EPS Growth (3Y)(%) 40.10
CTIX's EPS Growth (3Y)(%) is ranked higher than
88% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. CTIX: 40.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CTIX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 42.15 Max: 100
Current: 40.1
0
100
» CTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:NVIV, NAS:ITEK, NAS:IMGN, NAS:GLYC, NAS:ATHX, OTCPK:PAIOF, NAS:AGTC, NAS:PRTO, OTCPK:NICXF, AMEX:NAVB, OTCPK:SPRWF, NAS:CDTX, NAS:MDGL, NAS:RDHL, NAS:NYMX, NAS:VVUS, NAS:XENE, NAS:ABUS, NAS:VTL, OTCPK:SPHRY » details
Cellceutix Corp is a biopharmaceutical company. The Company is engaged in the business of developing small molecule therapies to treat diseases in the areas of cancer and inflammatory disease.

Cellceutix Corp was incorporated as Econoshare, Inc. on August 1, 2005, in the State of Nevada. On December 6, 2007, the Company acquired Cellceutix Pharma, Inc., a privately owned corporation formed under the laws of the State of Delaware on June 20, 2007. It is a clinical stage biopharmaceutical company developing therapies with oncology, dermatology and antimicrobial applications. It owns the rights to numerous drug compounds, including Kevetrin (thioureidobutyronitrile), an anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis; and Brilacidin. The Company's operations and activities are subject to extensive regulation by numerous government authorities in the United States and other countries.

Ratios

vs
industry
vs
history
P/B 68.82
CTIX's P/B is ranked lower than
98% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CTIX: 68.82 )
Ranked among companies with meaningful P/B only.
CTIX' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 338.2
Current: 68.82
0
338.2
Current Ratio 0.70
CTIX's Current Ratio is ranked lower than
92% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CTIX: 0.70 )
Ranked among companies with meaningful Current Ratio only.
CTIX' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.3 Max: 2.4
Current: 0.7
0.01
2.4
Quick Ratio 0.70
CTIX's Quick Ratio is ranked lower than
89% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. CTIX: 0.70 )
Ranked among companies with meaningful Quick Ratio only.
CTIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.3 Max: 2.4
Current: 0.7
0.01
2.4

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.60
CTIX's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CTIX: -7.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CTIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -114.3  Med: -8.15 Max: -0.1
Current: -7.6
-114.3
-0.1

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -9.20
CTIX's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CTIX: -9.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.45  Med: 0 Max: 0
Current: -9.2
-10.45
0

More Statistics

EPS (TTM) $ -0.11
Beta1.94
Short Percentage of Float0.00%
52-Week Range $0.95 - 1.92
Shares Outstanding (Mil)125.11
» More Articles for CTIX

Headlines

Articles On GuruFocus.com
Interview with CEO of Cellceutix Corporation: Leo Ehrlich Nov 15 2011 

More From Other Websites
Cellceutix Corp. :CTIX-US: Earnings Analysis: Q1, 2017 By the Numbers : November 29, 2016 Nov 29 2016
CELLCEUTIX CORP Financials Nov 17 2016
CELLCEUTIX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 15 2016
Cellceutix Provides Corporate Update and Reports Q1 Fiscal 2017 Financial Results Nov 14 2016
Cellceutix Announces Business Update Call at 10AM Eastern on November 15 Nov 09 2016
CELLCEUTIX CORP Files SEC form 10-Q, Quarterly Report Nov 09 2016
Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Severe Chronic Plaque... Oct 31 2016
Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple... Oct 26 2016
Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Novel Anti-Inflammatory... Oct 10 2016
Cellceutix Announces Appointment of Vice President for Regulatory Affairs Sep 16 2016
CELLCEUTIX CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 15 2016
Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones Sep 13 2016
CELLCEUTIX CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 13 2016
CELLCEUTIX CORP Files SEC form 10-K, Annual Report Sep 13 2016
Cellceutix Corporation to Present at Upcoming Conferences Sep 07 2016
MP Advisors Issues Research Report on Cellceutix Corporation Sep 01 2016
Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran Aug 30 2016
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug... Aug 03 2016
Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis Jul 21 2016
Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin... Jul 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)